ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Baudax Bio Inc (CE)

Baudax Bio Inc (CE) (BXRXQ)

0.000001
0.00
(0.00%)
Closed 08 December 8:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.000001
Bid
0.00
Offer
0.00
Volume
602
0.000001 Day's Range 0.000001
0.000001 52 Week Range 0.0205
Previous Close
0.000001
Open
0.000001
Last Trade
2
@
1.0E-6
Last Trade Time
Average Volume (3m)
4,906
Financial Volume
US$ 0
VWAP
0.000001

BXRXQ Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1001.0E-61.0E-61.0E-6260001.0E-6CS
4001.0E-61.0E-61.0E-6182561.0E-6CS
12001.0E-60.00021.0E-649062.717E-5CS
26-0.009929-99.98992950650.009930.011.0E-6275630.00566701CS
52-0.019999-99.9950.020.02051.0E-6580070.01128749CS
156-0.019999-99.9950.020.02051.0E-6580070.01128749CS
260-0.019999-99.9950.020.02051.0E-6580070.01128749CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PARNFParnell Pharmaceuticals Holdings Ltd (CE)
US$ 0.05
(4,999,900.00%)
20.19k
WPDPFWPD Pharmaceuticals Inc (PK)
US$ 0.001
(99,900.00%)
600
GXUSFGuardian Exploration Inc (QB)
US$ 0.0493
(49,200.00%)
3k
BYOCBeyond Commerce Inc (PK)
US$ 0.00014
(13,900.00%)
15.42M
WANSFCirata PLC (PK)
US$ 0.5261
(12,134.88%)
200
TEHGTechnovative Group Inc (CE)
US$ 0.000001
(-100.00%)
110
OOOOFOOOOO Entertainment Commerce Ltd (CE)
US$ 0.000001
(-99.99%)
11.5k
HAVLFHavn Life Sciences Inc (CE)
US$ 0.000001
(-99.98%)
667
PWWRFCleantech Power Corporation (CE)
US$ 0.000001
(-99.98%)
500
OFSIOmni Financial Services Inc (CE)
US$ 0.000001
(-99.78%)
500
HMBLHUMBL Inc (PK)
US$ 0.0023
(-11.54%)
1.53B
MJLBUltrack Systems Inc (PK)
US$ 0.0003
(100.00%)
612.64M
RDARRaadr Inc (PK)
US$ 0.002
(37.93%)
311.24M
GTCHGBT Technologies Inc (PK)
US$ 0.0001
(0.00%)
274.75M
NAFSNorth America Frac Sand Inc (PK)
US$ 0.0001
(-50.00%)
170.55M

BXRXQ Discussion

View Posts
Daniel Plainview Daniel Plainview 9 months ago
What the hell?
👍️0
Renee Renee 9 months ago
BXRX changed to BXRXQ, bankruptcy:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Daniel Plainview Daniel Plainview 10 months ago
Adding More !
👍️0
Daniel Plainview Daniel Plainview 10 months ago
We are over due for a move up....$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 11 months ago
Fire-up baby....$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 11 months ago
It's going to take off....$$$$$$$$$
👍️0
surf1944 surf1944 11 months ago
Market Cap Market Cap
1,243,309
01/02/2024
Authorized Shares
190,000,000
01/02/2024
Outstanding Shares
52,460,302
01/02/2024
Restricted
27,988,576
01/02/2024
Unrestricted
24,471,726
01/02/2024
Held at DTC
24,471,707
01/02/2024
👍️0
harry crumb harry crumb 11 months ago
What happened to this?? Not listed anymore
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 11 months ago
$BXRX
https://x.com/hannahadad8890/status/1739952364763664723?s=61
👍️0
Daniel Plainview Daniel Plainview 11 months ago
It's taking off...$$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 12 months ago
It doesn't take much to move this baby up....$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 12 months ago
You will start seeing more people coming into this room volume jumping.
👍️0
Daniel Plainview Daniel Plainview 12 months ago
I've been loading starting to like what I see volume rising they are due.
👍️0
Daniel Plainview Daniel Plainview 12 months ago
I'm thinking the same.
👍️0
surf1944 surf1944 12 months ago
https://stockcharts.com/h-sc/ui?s=bxrx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/bxrx/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/bxrx/opinion

https://finance.yahoo.com/quote/bxrx/

Buying on weakness for Jan bounce!
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 12 months ago
$BXRX
https://x.com/hannahadad8890/status/1736384058064572548?s=61
👍️0
Daniel Plainview Daniel Plainview 12 months ago
Something's going on here starting to spike...$$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 12 months ago
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Come on baby fire up.
👍️0
harry crumb harry crumb 1 year ago
Anybody kno what happened to this scam?
👍️0
splintered sunlight splintered sunlight 1 year ago
You're probably right but there is a little money to be made before it gets there LOL......
👍️0
Daniel Plainview Daniel Plainview 1 year ago
We need some kind of a spark to get this thing going.
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Good lord this thing is going down to trips.
👍️0
splintered sunlight splintered sunlight 1 year ago
Anybody trading this?
👍️ 1
splintered sunlight splintered sunlight 1 year ago
Yes
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Sucks !
👍️0
splintered sunlight splintered sunlight 1 year ago
Not immediately, but give it time......
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Damn trips here we come.
👍️0
Renee Renee 1 year ago
BXRX delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Added More !....$$$$$$$$$$$$$
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Looks like we might just have another green day
👍️0
glenn1919 glenn1919 1 year ago
BXRX...........................https://stockcharts.com/h-sc/ui?s=BXRX&p=W&b=5&g=0&id=p86431144783
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Good news coming out....A++++++++
👍️0
Daniel Plainview Daniel Plainview 1 year ago
When this hits it's going to take off like a rocket...$$$$$$
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Looks like it could run...$$$$$$$$
👍️0
weedtrader420 weedtrader420 1 year ago
NICE!
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Volume just isn't there to push it "Rats Ass"
👍️0
Daniel Plainview Daniel Plainview 1 year ago
Damn going back down again.
👍️0
TheFinalCD TheFinalCD 1 year ago
https://dilutiontracker.com/app/search/BXRX
👍️0
weedtrader420 weedtrader420 1 year ago
BXRX💫🤑 Dance Monkey
👍️0
subslover subslover 1 year ago
Baudax Bio Announces Corporate Update
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition

Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024

MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that following recent shareholder approval of corporate actions related to its June 29 2023 acquisition of TeraImmune, the Company is now poised to initiate clinical development of TI-168, the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors. The Company anticipates initiating its Phase 1/2a clinical study of TI-168 in Hemophilia A patients with FVIII inhibitors with a modest initial budget in Q1 of 2024.

“We are very pleased with the broad support received in last week’s special shareholder meeting, during which shareholders approved all remaining issues related to our acquisition of TeraImmune,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. “We believe this combination, which brings together TeraImmune’s research expertise with Baudax’s drug development experience for the initiation of clinical development of TI-168, represents the best path forward to create shareholder value. With shareholder support now secured, we can finalize our preparations for initiating a Phase 1/2a clinical study of TI-168 in Hemophilia A patients in Q1 of 2024.”

Stewart Mc Callum, MD, Consulting Chief Medical Officer for Baudax, added, “TI-168 is a TCR Treg designed to eliminate autoantibodies to Factor VIII in Hemophilia A patients, which significantly complicates the management of Hemophilia A. This product candidate previously had an IND filed seeking to treat human subjects that received regulatory clearance, and has also recently been granted Orphan Drug Designation by the FDA. Since our trial has an open label design, we anticipate early visibility on tolerability and initial efficacy data.”

“This trial represents the first time that TCR Tregs will be in a human clinical trial, and will seek to establish a dose where TI-168 eliminates T-cell and B cell mediated production of autoantibodies, demonstrating the potential of TI-168 to make Hemophilia A much less complicated for patients with inhibitors to manage. We are very excited for the opportunity to work toward this potential improvement to patient quality of life, and to deliver enhanced value for our shareholders and other stakeholders,” concluded Ms. Henwood.

About Baudax Bio

Baudax Bio is a biotech company focused on innovative products for certain auto-immune conditions, of which many but not all, are orphan drug conditions as well as acute care and related settings. The combined company will further the development of Treg therapy specific to HA (pipeline candidate TI-168). TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. By combining the patented Treg culture method and TeraImmune designed FVIII-specific TCR, the Company has successfully demonstrated the therapeutic concept of FVIII TCR-Treg therapy in controlling of FVIII ADA in a hemophilic animal model. The lead program TI-168 has shown encouraging pre-clinical data and the FDA has cleared an IND to commence a Phase 1/2a clinical trial for the treatment of Hemophilia A with inhibitors.

In addition, over time, the combined company will advance the development of TeraImmune’s innovative immune-cell therapies, leveraging a dual Treg manufacturing platform consisting of both natural regulatory Tregs isolated from patients and induced Tregs converted from a patient’s T-effector (“Teff”) cells. This Treg platform technology is designed for conditions that suppress unwanted immune reactions and includes the allogenic, or off-the-shelf, Tregs obtained from Umbilical Cord Blood for the treatment of skin diseases such as Atopic Dermatitis. For more information, please visit www.baudaxbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio, are intended to identify such forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Baudax Bio’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, clinical results and other future conditions. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in Baudax Bio’s most recent Annual Report on Form 10-K filed with the SEC and its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Baudax Bio, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Baudax Bio’s views as of any date subsequent to the date hereof.

Investor Relations Contact:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

https://www.globenewswire.com/newsroom/ti?nf=ODk1MTIxMSM1ODc4NDU4IzUwMDExNjY0NA==
https://ml.globenewswire.com/media/M2Q0YjRlODktY2E4NC00YjI5LWFhYWMtNDU3NWQ4Zjg3Y2ZkLTUwMDExNjY0NA==/tiny/Baudax-Bio.png

Source: Baudax Bio
👍️0
weedtrader420 weedtrader420 1 year ago
I was loading last night under $.20 that was ridiculous
👍️0
Awl416 Awl416 1 year ago
Loaded? There was only $7500 traded AH

👍️0
weedtrader420 weedtrader420 1 year ago
BXRX💫 THE PARTY HAS BEGUN 🚛💰💰💰💰💰💰💰
👍️0
weedtrader420 weedtrader420 1 year ago
BXRX💫 This a Journey into Sound
👍️0
weedtrader420 weedtrader420 1 year ago
WOW!🤑🤑🤑🤑🤑BXRX💫
👍️0
weedtrader420 weedtrader420 1 year ago
WOOHOOOOOO WOOHOOOOOO I loaded this baby last night WOOHOOOOOO
👍️0
Monksdream Monksdream 1 year ago
BXRX new 52 week low
👍️0
trendzone trendzone 1 year ago
The criminals know that there could be an offering coming, and that they could easily manipulate it down from its days high, off of that most of the volume was day traders who would sell out if it rolled over,knowing that there wouldn't be many wanting to take it over night on concerns about an offering, so they turned their machines of criminal manipulation on and shorted it down, if there was any news of a cancelation of the possible offering,the scm bags and their shorting machines would get hit so hard,they wouldn't no what hit them,and blown them out squeezed into the ground.
👍️0
seko19822 seko19822 1 year ago
LIFW is today the next. Look at the chart
👍️ 1

Your Recent History

Delayed Upgrade Clock